Technical Analysis for CGEN - Compugen Ltd.

Grade Last Price % Change Price Change
C 2.67 -2.20% -0.06
CGEN closed down 2.2 percent on Monday, March 18, 2024, on 42 percent of normal volume.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
NR7 Range Contraction -2.20%
Narrow Range Bar Range Contraction -2.20%
Inside Day Range Contraction -2.20%
MACD Bearish Signal Line Cross Bearish -0.37%
Calm After Storm Range Contraction -4.98%
Wide Bands Range Expansion -4.98%
Calm After Storm Range Contraction -4.64%
NR7 Range Contraction -4.64%
Wide Bands Range Expansion -4.64%

   Recent Intraday Alerts

Alert Time
Down 2 % about 9 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
Down 1% about 15 hours ago
10 DMA Resistance about 15 hours ago
10 DMA Support about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Compugen Ltd. Description

Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Life Sciences Immunology Autoimmune Disease Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Therapeutic Products Biomarkers Autoimmunity Multiple Myeloma Rheumatoid Arthritis Multiple Sclerosis Autoimmune Disorders Immune Disorders Fusion Protein Compugen Monoclonal Antibody Therapy Treatment Of Multiple Sclerosis Antibody Therapy

Is CGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.0301
52 Week Low 0.53
Average Volume 762,513
200-Day Moving Average 1.35
50-Day Moving Average 2.31
20-Day Moving Average 2.63
10-Day Moving Average 2.72
Average True Range 0.21
RSI (14) 54.75
ADX 30.35
+DI 27.95
-DI 18.06
Chandelier Exit (Long, 3 ATRs) 2.41
Chandelier Exit (Short, 3 ATRs) 2.82
Upper Bollinger Bands 2.98
Lower Bollinger Band 2.28
Percent B (%b) 0.56
BandWidth 26.59
MACD Line 0.14
MACD Signal Line 0.16
MACD Histogram -0.0206
Fundamentals Value
Market Cap 235.83 Million
Num Shares 88.3 Million
EPS -0.37
Price-to-Earnings (P/E) Ratio -7.22
Price-to-Sales 25.20
Price-to-Book 3.55
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.90
Resistance 3 (R3) 2.91 2.86 2.86
Resistance 2 (R2) 2.86 2.80 2.85 2.84
Resistance 1 (R1) 2.76 2.76 2.74 2.75 2.83
Pivot Point 2.71 2.71 2.69 2.70 2.71
Support 1 (S1) 2.61 2.65 2.59 2.60 2.51
Support 2 (S2) 2.56 2.61 2.55 2.50
Support 3 (S3) 2.46 2.56 2.48
Support 4 (S4) 2.45